Abstract
Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1387-1396 |
| Number of pages | 10 |
| Journal | Journal of Thoracic Oncology |
| Volume | 11 |
| Issue number | 9 |
| DOIs | |
| State | Published - 2016 |
Keywords
- Clinical trials
- Immunotherapy
- Lung cancer
- Targeted therapy
Fingerprint
Dive into the research topics of 'Clinician perspectives on current issues in lung cancer drug development'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver